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Abstract
The objective of this study is to characterize the seroprevalence of anti-dengue (DENV) and
anti-chikungunya (CHIKV) antibodies among blood donors residing in Qatar who are Middle
East and North Africa (MENA) nationals and non-nationals. Sera were collected from adult
blood donors in Qatar from 2013 to 2016 and tested for anti-DENV and anti-CHIKV IgG
using commercial microplate enzyme-linked immunosorbent assays. Age-specific seroprev-
alence was summarized by region/nationality: Asia (India, Philippines), Middle East (Iran,
Jordan, Lebanon, Pakistan, Palestine, Syria, Yemen), North Africa (Egypt, Sudan), Qatar.
The adjusted odds of anti-DENV and anti-CHIKV IgG seropositivity was estimated by logis-
tic regression. Among 1,992 serum samples tested, Asian nationals had higher adjusted
odds of being seropositive for anti-DENV antibodies compared to nationals of the Middle
East (aOR 0.05, 95% CI 0.04–0.07), North Africa (aOR 0.14, 95% CI 0.10–0.20), and Qatar
(aOR 0.01, 95% CI 0.01–0.03). Asian nationals also had higher adjusted odds of being sero-
positive for anti-CHIKV antibodies compared to those from the Middle East (aOR 0.14, 95%
CI 0.07–0.27), North Africa (aOR 0.50, 95% CI 0.26–0.96), and Qatar (aOR 0.38, 95% CI
0.15–0.96). The adjusted odds of being anti-DENV seropositive was higher among anti-
CHIKV seropositive adults, and vice versa (aOR 1.94, 95% CI 1.09–3.44), suggesting
co-circulation of these viruses. DENV and CHIKV exposure is lower in Qatar and MENA
nationals compared to Asian nationals suggesting a lower burden of DENV and CHIKV dis-
ease in the MENA. Antibodies to both viruses were detected in nationals from most MENA
countries, supporting the need to better understand the regional epidemiology of these
viruses.
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Introduction
Although dengue (DENV) and chikungunya (CHIKV) viruses rank among the most impor-
tant causes of arboviral diseases in the world, their epidemiology in the Middle East and North
Africa (MENA) is sparsely characterized [1, 2]. Recent outbreaks of DENV and CHIKV have
been documented in several MENA countries including Pakistan, Sudan, and Yemen, while in
over half of MENA countries, no seroprevalence data has ever been published [1–8]. In Qatar,
neither local transmission of DENV or CHIKV, nor the presence of their principal vectors,
Aedes aegypti and Aedes albopictus, has yet been reported to our knowledge. However, the
expansion of DENV in neighboring Saudi Arabia and Yemen underscores the importance of
understanding the epidemiology of these pathogens and their potential for spread in Qatar
and the surrounding region.
Qatar is situated on the northeastern coast of the Arabian Peninsula, surrounded by the
Arabian Gulf and bordering Saudi Arabia to the south (Fig 1). Rainfall is infrequent (<100
mm annually) and average high temperatures often exceed 38˚C [9]. Modeling studies have
identified low probability of occurrence of Ae. aegypti in Qatar on account of poor environ-
mental suitability (e.g. high temperature, low precipitation), but potential for Ae. albopictus
occurrence in urban areas of Qatar [10]. Still, Qatar has various characteristics that could influ-
ence the potential for local DENV and CHIKV transmission and present a unique opportunity
to study the seroepidemiology of these viruses in the MENA. First, 88% of the country’s 2.2
million people are migrants from other countries [11]. Up to 60% of these migrants come
from the Indian subcontinent and the Philippines, posing risk of imported infections from
some of the most highly DENV and CHIKV endemic countries in the world [12–14]. Second,
MENA nationals from Egypt, Pakistan, Syria, Sudan, Jordan, Iran, and Lebanon are estimated
to make up approximately 22% of the country’s population [15]. In most of these countries,
local DENV or CHIKV transmission, serologic evidence of past infection, or the presence of
Ae. aegypti or Ae. albopictus has been documented, yet published epidemiologic data is
lacking.
Blood donor serosurveys can be an efficient means of gaining preliminary insight into the
epidemiology and potential burden of these viruses in this circumstance. Few blood donor
Fig 1. Represented countries (n = 12) among Qatari nationals and immigrants residing in Qatar who were included in the study.
https://doi.org/10.1371/journal.pone.0211574.g001
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surveys have ever been conducted for DENV and CHIKV in the MENA region, and none have
sampled nationals from other countries or compared prevalence to non-MENA nationals [16–
22]. The objective of this study is to characterize the seroprevalence of anti-DENV and anti-
CHIKV antibodies among blood donors residing in Qatar who are MENA and non-MENA
nationals. Such data will address knowledge gaps in our understanding of the seroepidemiol-
ogy of these pathogens in the MENA region, and their potential risk of emergence in Qatar.
Methods
Ethics statement
The research work was approved by the ethics boards and research committees at Qatar Uni-
versity, Hamad Medical Corporation, and Weill Cornell Medicine-Qatar. The requirement for
informed consent was waived by these institutions given that samples were already de-identi-
fied at the time they were received for this research. All experiments were performed in accor-
dance with relevant guidelines and regulations.
Study design and participants
This was a retrospective, cross-sectional study using de-identified blood samples collected
from volunteer blood donors attending Hamad Medical Corporation in Qatar, the largest
healthcare provider in the country, from June 2013 to June 2016. In total, 5,973 blood donors
consented to submit blood specimens and basic demographic information (age, nationality,
gender) which were analyzed in other studies [23–28]. A subset of this biobank, selected at ran-
dom, was analyzed for this study. The original sample set included male and female Qataris
and expatriates (MENA and non-MENA nationals) who were� 18 years of age and residing
in Qatar. In total, there were 5,799 men and 152 women, with gender type missing in 0.4%
(n = 22) of participants, which served as the original sampling cohort for selection of the final
sample. Given the low number of available samples from women, only samples from men
were included in our study.
Sample sizes were calculated for a significance level of α = 0.05. A minimum sample size of
100 was estimated for each country based on a projected overall anti-DENV antibody sero-
prevalence of 25% with 9% precision and an anti-CHIKV antibody prevalence of 1% with 2%
precision [1, 2]. However, up to 200 samples were analyzed per country based on sample avail-
ability in order to increase the precision of the estimates. Attrition did not need to be
accounted for, as it is minimal, given that a sufficient quantity of blood donor samples was
known to be available from our prior studies of the seroprevalence of herpes simplex viruses
[27, 28].
Biological sample collection and laboratory analysis
A total of 20 μL of serum was aliquoted from each participant’s sample that had been stored at
-80˚C. Sera were tested for the presence of anti-DENV and anti-CHIKV IgG (10 μL serum for
each test) using commercial microplate enzyme linked immunosorbent assay (ELISA) kits for
anti-DENV (NovaTec Immundiagnostica GmbH, Frankfurt, Germany, DENG0120) and anti-
CHIKV (Euroimmun, Lübeck, Germany, EI 293a-9601 G) antibodies [29, 30]. These kits are
designed for monospecific determination of IgG antibodies with 3-point quantitative calibra-
tion and approved by the United States Food and Drug Administration. As per the manufac-
turer, the anti-DENV IgG ELISA is based on purified virus particles of serotype 2, allowing for
detection of virus serotypes 1–4 based on the structural similarities between them [31]. The
sensitivity and specificity was 100% and 97%, respectively, in clinically characterized sera,
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though cross-reactions with other flaviviruses can occur [20]. The anti-CHIKV ELISA uses a
virus-specific structural protein as the antigenic substrate with a sensitivity and specificity of
95% and 88%, respectively [32]. Cross-reactions against o’nyong-nyong virus and Mayaro
virus were observed in this latter study [32].
Data analysis
For each virus, the proportion of positive samples was summarized with 95% confidence inter-
vals (CI) according to nationality and age across seven bands:� 24, 25–29, 30–34, 35–39, 40–
44, 45–49, and� 50 years. Age-specific seroprevalence for each virus was also cross-tabulated
by region: Asia (India, Philippines), Middle East (Iran, Jordan, Lebanon, Pakistan, Palestine,
Syria, Yemen), North Africa (Egypt, Sudan), and Qatar. Regions were defined according to the
MENA definitions of the World Health Organization Regional Office for the Eastern Mediter-
ranean (WHO/EMRO), the Joint United Nations Programme on HIV/AIDS (UNAIDS), and
the Word Bank, and for consistency with our earlier dengue, chikungunya, and HIV regional
publications [1, 2, 33–36]. Associations between nationality, age and seropositivity were sum-
marized with odds ratios (ORs) and 95% CIs. Logistic regression was used to estimate the
adjusted effects of age and regional nationality on the odds of seropositivity for anti-DENV
and anti-CHIKV IgG separately, as well as the odds of anti-DENV IgG positivity in the setting
of anti-CHIKV IgG positivity, and vice versa. Significance level was defined at α = 0.05. Data
was analyzed using the Statistical Package for the Social Sciences (SPSS) version 24.
Results
A total of 1,992 serum samples from male subjects� 18 years of age from 12 countries were
tested for anti-DENV and anti-CHIKV IgG antibodies (Fig 1 and Table 1). The number of
samples tested per country ranged from 97 (< 100 due to insufficient serum) to 200. The
median [IQR] age of subjects was 36 [30–43] years. Anti-DENV IgG was detected in six or
more samples from individuals from every country, while anti-CHIKV IgG was detected in at
least one sample from individuals from every country except Iran. The country-specific overall
seroprevalence for anti-DENV IgG ranged from 3.5% (95% CI 1.6–6.8%) in Qatar to 95.8%
(95% CI 91.0–98.4%) in the Philippines. For anti-CHIKV IgG, overall seroprevalence ranged
from 0% in Iran to 17.7% (95% CI 11.6–25.2%) in the Philippines.
Table 1. Country-specific seroprevalence for anti-DENV IgG and anti-CHIKV IgG among subjects residing in Qatar but from different countries, from June 2013
to June 2016.
Country Sample size Prevalence
Anti-DENV IgG
positive
% (95% CI) Anti-CHIKV IgG
positive
% (95% CI)
Egypt 199 40 20.1 (15.0–26.1) 11 5.5 (3.0–9.4)
India 200 125 62.5 (55.7–70.0) 22 11.0 (7.2–15.9)
Iran 113 6 5.3 (2.3–10.6) 0 0 (0)
Jordan 199 9 4.5 (2.3–8.1) 1 0.5 (0.1–2.3)
Lebanon 116 6 5.2 (2.2–10.4) 1 0.9 (0.1–4.0)
Pakistan 200 40 20.0 (14.9–26.0) 3 1.5 (0.3–4.3)
Palestine 200 17 8.5 (5.2–13.0) 6 3.0 (1.2–6.1)
Philippines 119 114 95.8 (91.0–98.4) 21 17.7 (11.6–25.2)
Qatar 200 7 3.5 (1.6–6.8) 7 3.5 (1.6–6.8)
Sudan 97 47 48.5 (38.7–58.3) 5 5.2 (2.0–10.9)
Syria 200 26 13.0 (8.9–18.2) 1 0.5 (0.1–2.3)
Yemen 149 36 24.2 (17.8–31.5) 4 2.7 (0.9–6.3)
https://doi.org/10.1371/journal.pone.0211574.t001
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The overall and age-specific seroprevalence for each virus was also estimated for nationals
residing in Qatar but from Asia, Middle East, North Africa, and Qatar (Tables 2 and 3). Age-
specific seroprevalence values were significantly different across regions for both viruses in all
age groups (P< 0.05 for all), with the exception of anti-CHIKV IgG seroprevalence for
adults� 50 years (P = 0.20). Overall, the highest seroprevalence estimates for anti-DENV IgG
occurred among Asian nationals (74.8% seropositive, 95% CI 69.7–79.5%) and the lowest
among Qatari nationals (3.5% seropositive, 95% CI 1.4–7.1%). For anti-CHIKV IgG, the high-
est seroprevalence also occurred among Asian nationals (13.5% seropositive, 95% CI 10.0–
17.8%), and the lowest among Middle East nationals (1.4% seropositive, 95% CI 0.8–2.2%).
Regional nationality was significantly associated with the odds of being anti-DENV and
anti-CHIKV IgG seropositive in the unadjusted and adjusted models (P< 0.05 for all;
Table 4).
Table 2. Estimates of age-specific anti-DENV IgG seroprevalence among blood donors currently residing in Qatar but from Asia (India, Philippines), Middle East
(Iran, Jordan, Lebanon, Pakistan, Palestine, Syria, Yemen), North Africa (Egypt, Sudan), and Qatar, from June 2013 to June 2016.
Age group Asiaa Middle Eastb North Africa Qatar P valuec
Years N+ / Total % (95% CI) N+ / Total % (95% CI) N+ / Total % (95% CI) N+ / Total % (95% CI)
� 24 7 / 15 46.7 (23.9–70.6) 9 / 111 8.1 (4.1–14.3) 2 / 19 10.5 (2.3–29.7) 0 / 16 0 (0–0) <0.001
25–29 42 / 56 75.0 (62.6–84.9) 12 / 167 7.2 (4.0–11.9) 22 / 61 36.1 (24.9–48.5) 0 / 33 0 (0–0) <0.001
30–34 65 / 85 76.5 (66.7–85.0) 31 / 238 13.0 (9.2–17.7) 17 / 64 26.6 (17.0–38.3) 2 / 35 5.7 (1.2–17.1) <0.001
35–39 47 / 61 77.1 (65.4–86.2) 29 / 231 12.6 (8.8–17.3) 20 / 66 30.3 (20.2–42.1) 1 / 38 2.6 (0.3–11.7) <0.001
40–44 32 / 43 74.4 (60.1–85.6) 23 / 198 11.6 (7.7–16.6) 13 / 36 36.1 (22.0–52.4) 2 / 35 5.7 (1.2–17.1) <0.001
45–49 32 / 41 78.1 (63.8–88.6) 13 / 111 11.7 (6.7–18.7) 4 / 20 20.0 (7.2–40.8) 2 / 20 10.0 (2.1–28.4) <0.001
� 50 13 / 17 76.5 (53.3–91.5) 23 / 119 19.3 (13.0–27.1) 9 / 30 30 (16.0–47.7) 0 / 23 0 (0–0) <0.001
Total 238 / 318 74.8 (69.7–79.5) 140 / 1175 11.9 (10.1–13.9) 87 / 296 29.4 (24.3–34.9) 7 / 200 3.5 (1.4–7.1) <0.001
“N+” indicates number of positive samples.
a Age information was missing for one individual.
b Age information was missing for two individuals.
c P value for differences between regions.
https://doi.org/10.1371/journal.pone.0211574.t002
Table 3. Estimates of age-specific anti-CHIKV IgG seroprevalence among blood donors currently residing in Qatar but from Asia (India, Philippines), Middle East
(Iran, Jordan, Lebanon, Pakistan, Palestine, Syria, Yemen), North Africa (Egypt, Sudan), and Qatar, 2013–2016.
Age group Asiaa Middle Eastb North Africa Qatar P valuec
Years N+ / Total % (95% CI) N+ / Total % (95% CI) N+ / Total % (95% CI) N+ / Total % (95% CI)
� 24 2 / 15 13.3 (2.9–36.3) 2 / 111 1.8 (0.4–5.7) 0 / 19 0 (0–0) 0 / 16 0 (0–0) 0.039
25–29 7 / 56 12.5 (5.8–23.0) 4 / 167 2.4 (0.8–5.6) 3 / 61 4.9 (1.4–12.6) 1 / 33 3.0 (0.3–13.3) 0.026
30–34 10 / 85 11.8 (6.21–19.9) 3 / 238 1.3 (0.4–3.3) 4 / 64 6.3 (2.2–14.2) 3 / 35 8.6 (2.5–21.1) <0.001
35–39 5 / 61 8.2 (3.2–17.0) 1 / 231 0.4 (0.1–2.0) 4 / 66 6.1 (2.1–13.8) 0 / 38 0 (0–0) 0.001
40–44 9 / 43 20.9 (10.9–34.7) 3 / 198 1.5 (0.4–4.0) 1 / 36 2.8 (0.3–12.3) 1 / 35 2.9 (0.3–12.6) <0.001
45–49 8 / 41 19.5 (9.7–33.5) 0 / 111 0 (0–0) 3 / 20 15.0 (4.4–34.9) 1 / 20 5 (0.5–21.1) <0.001
� 50 2 / 17 11.8 (2.5–32.7) 3 / 119 2.5 (0.7–6.6) 1 / 30 3.3 (0.4–14.5) 1 / 23 4.3 (0.5–18.6) 0.203
Total 43 / 318 13.5 (10.0–17.8) 16 / 1175 1.4 (0.8–2.2) 16 / 296 5.4 (3.1–8.6) 7 / 200 3.5 (1.4–7.1) <0.001
“N+” indicates number of positive samples.
a Age information was missing for one individual.
b Age information was missing for two individuals.
c P value for differences between regions.
https://doi.org/10.1371/journal.pone.0211574.t003
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Asian nationals had higher adjusted odds of being seropositive for anti-DENV antibodies
compared to nationals of the Middle East (aOR 0.05, 95% CI 0.04–0.07), North Africa (aOR
0.14, 95% CI 0.10–0.20), and Qatar (aOR 0.01, 95% CI 0.01–0.03). Asian nationals also had
higher adjusted odds of being seropositive for anti-CHIKV antibodies compared to those from
the Middle East (aOR 0.14, 95% CI 0.07–0.27), North Africa (aOR 0.50, 95% CI 0.26–0.96),
and Qatar (aOR 0.38, 95% CI 0.15–0.96). Increasing age was also significantly associated with
anti-DENV IgG seroprevalence, with individuals� 50 years of age having 3.18 times (95% CI
1.61–6.28) the adjusted odds of being anti-DENV IgG seropositive compared to individuals�
24 years of age (Table 4). However, age was not significantly associated with the adjusted odds
of seropositivity for anti-CHIKV IgG. Finally, the adjusted odds of being anti-DENV IgG sero-
positive was significantly higher among anti-CHIKV IgG seropositive adults, and vice versa
(aOR 1.94, 95% CI 1.09–3.44).
Discussion
In our study, anti-DENV and anti-CHIKV IgG prevalences were significantly lower among
blood donors residing in Qatar who were MENA nationals compared to Asian nationals,
though antibodies to both viruses were detected from donors in all regions. This finding
underscores the need to better understand the distribution and epidemiology of these patho-
gens in the MENA region, but it suggests that the overall burden of DENV and CHIKV disease
is higher in India and the Philippines than in the MENA countries represented in our study.
The results also suggest regional variability within the MENA region.
Our study is the first, to our knowledge, to estimate the seroprevalence of anti-DENV and
anti-CHIKV IgG among nationals of Qatar and Syria [1, 2]. We cannot be certain that individ-
uals from these countries developed antibodies as a result of DENV and CHIKV exposure in
their home countries or Qatar rather than through traveling or residing in other endemic
Table 4. Unadjusted and adjusted odds ratios for anti-DENV IgG and anti-CHIKV IgG seropositivity among blood donors residing in Qatar but from different
regions.
Characteristic Unadjusted Odds Ratio Adjusted Odds Ratioa
Anti-DENV IgG
UOR (95% CI)
P value Anti-CHIKV IgG
UOR (95% CI)
P value Anti-DENV IgG
AOR (95% CI)




Asia Ref Ref Ref Ref
Middle East 0.05 (0.03–0.06) <0.001 0.09 (0.05–0.16) <0.001 0.05 (0.04–0.07) <0.001 0.14 (0.07–0.27) <0.001
North Africa 0.14 (0.10–0.20) <0.001 0.37 (0.20–0.67) 0.001 0.14 (0.10–0.20) <0.001 0.50 (0.26–0.96) 0.038
Qatar 0.01 (0.01–0.03) <0.001 0.23 (0.10–0.53) <0.001 0.01 (0.01–0.03) <0.001 0.38 (0.15–0.96) 0.041
Age group (years)
� 24 Ref Ref Ref Ref
25–29 2.51 (1.44–4.36) 0.001 1.95 (0.64–5.97) 0.243 1.20 (1.05–3.79) 0.035 1.23 (0.39–3.89) 0.721
30–34 2.98 (1.74–5.08) <0.001 1.95 (0.66–5.80) 0.229 2.38 (1.28–4.41) 0.006 1.21 (0.40–3.70) 0.740
35–39 2.58 (1.50–4.43) 0.001 1.02 (0.31–3.29) 0.978 2.42 (1.30–4.51) 0.006 0.69 (0.21–2.29) 0.541
40–44 2.30 (1.32–4.01) 0.003 1.84 (0.60–5.70) 0.288 2.40 (1.25–4.56) 0.008 1.42 (0.45–4.52) 0.551
45–49 2.87 (1.60–5.16) <0.001 2.62 (0.83–8.28) 0.102 2.26 (1.13–4.50) 0.021 1.65 (0.51–5.42) 0.406
� 50 2.48 (1.37–4.50) 0.003 1.51 (0.43–5.25) 0.517 3.18 (1.61–6.28) 0.001 1.28 (0.36–4.59) 0.704
Anti-DENV IgG positive — — 4.68 (2.98–7.34) <0.001 — — 1.94 (1.09–3.44) 0.024
Anti-CHIKV IgG positive 4.68 (2.98–7.34) <0.001 — — 1.94 (1.09–3.44) 0.024 — —
a Adjusted for nationality, age, and other arbovirus seropositivity (i.e. anti-DENV seropositivity status as predictor of anti-CHIKV seropositivity, and vice versa). For
this analysis, n = 1,989 given missing age information for three individuals.
https://doi.org/10.1371/journal.pone.0211574.t004
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countries, or that these antibodies definitively represent prior exposure and not cross-reactions
to other pathogens. Nevertheless, these detections suggest the possibility of low, but potentially
unrecognized, transmission of DENV and CHIKV in these MENA countries.
Consistent with many other studies, older age was significantly associated with increased
odds of DENV exposure in our study [37–40]. Immunity for the infecting DENV serotype (i.e.
detection of serum neutralizing antibodies) is considered to be lifelong, though homotypic
reinfections (i.e. reinfection by the same serotype) can occur [41, 42]. Hence, the increased
odds of DENV exposure with age is in part a function of longer exposure time. Age was not
associated with CHIKV exposure in our study, though this association has been observed for
CHIKV [37]. Detection of this association may have been limited by the small proportion of
CHIKV seropositive samples in our study and that many (41%) participants were 30–39 years
of age (generally reflective of the migrant demographic in Qatar) with variable sample sizes in
each age group. As a secondary analysis, we grouped countries by overall seroprevalence levels:
high (>30% seroprevalence: India, Philippines, Sudan), medium (15–30% seroprevalence:
Egypt, Pakistan, Yemen) and low (<15% seroprevalence: Iran, Jordan, Lebanon, Palestine,
Qatar, Syria). These seroprevalence values represent practical cutoffs based on the country-
level seroprevalences in our study, as there is currently no consensus to classify population
seroprevalence as high or low for either virus to our knowledge. However, this did not result
in meaningful changes in any of the aforementioned associations compared to the primary
analysis. Finally, the adjusted odds of anti-DENV IgG seropositivity was nearly twice as high
among anti-CHIKV IgG seropositive individuals compared to seronegative individuals, which
is consistent with the co-circulation of these viruses as a result of their shared vectors Ae.
aegypti and Ae. albopictus, and suggests the common source exposure to subjects for both
pathogens.
Dengue in the MENA region
Anti-DENV IgG antibodies were identified among nationals of all countries in our study, with
the highest prevalence among Asian nationals (India 62.5% and Philippines 95.8%). Among
MENA nationals, those from Sudan (48.5%), Yemen (24.2%), and Pakistan (20.0%) had the
highest seroprevalence. This is consistent with the epidemiologic literature, as available studies
suggest DENV is widely endemic in Sudan with seroprevalence of 9–49% among general pop-
ulations, and multiple outbreaks have occurred along the Red Sea coast since the 1980s [5, 43–
47]. The risk of DENV exposure may be similarly high in Yemen, in which recent outbreaks
have resulted in 19–87% seroprevalence among general populations [8, 48–51]. In Pakistan,
serologic and outbreak data suggest DENV is distributed across the country [52–56].
Our present study also identified 5–13% seroprevalence among nationals from Lebanon,
Palestine, and Syria, in which no reports of DENV have been published in decades [57, 58].
However, Ae. albopictus and/or Ae. aegypti have been recently reported in these countries, and
there are historic reports of DENV transmission in Lebanon, raising the potential for unrecog-
nized transmission or future emergence in these countries [57, 59, 60]. Additionally, our study
identified 20.1% seroprevalence among Egyptian nationals. Ae. aegypti is known to be endemic
in Egypt and an outbreak was reported in 2015 along the Red Sea Coast, although there is cur-
rently a paucity of literature describing the epidemiology of DENV in the country [61–63]. In
Jordan, anti-DENV IgG was recently detected in 24% of 892 healthy individuals distributed
across the country, representing the first report of anti-DENV seroprevalence in Jordan [64].
As with our data, these data are not direct evidence for local DENV transmission in Jordan,
but suggest its possibility. Finally, our study identified 5.3% seroprevalence among Iran
nationals, despite no published reports to our knowledge of DENV transmission or Ae. aegypti
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occurrence in Iran. However, prior studies have shown 3–7% seroprevalence near the Pakistan
border of the country [17, 65, 66]. Vector surveillance is critical in these countries, both to
evaluate the risk of DENV transmission and to implement preventive vector control strategies
and active case surveillance as indicated.
Chikungunya in the MENA region
Seroprevalence estimates for anti-CHIKV IgG were significantly lower than anti-DENV IgG
estimates in all countries in our study, which is consistent with the current serologic evidence
in the MENA region and suggests a lower overall burden of CHIKV disease compared to
DENV [2]. Yet although the CHIKV seropositivity was proportionally smaller, the country-
level anti-CHIKV IgG proportions were similarly distributed to those of anti-DENV IgG in
that those nationals with the highest CHIKV exposure (Philippines, India, Sudan) also had the
highest DENV exposure. This supports an overlapping distribution of DENV and CHIKV
among the countries represented in our study, on account of the viruses’ shared mosquito vec-
tors, Ae. aegypti and Ae. albopictus [13].
Our study identified 0.5–3.0% anti-CHIKV IgG seroprevalence in Jordan, Lebanon, Pales-
tine and Syria. There have been no published reports of CHIKV transmission in these coun-
tries to our knowledge. Given the additional lack of confirmed DENV transmission in these
countries, this raises the probability that these results are either false-positive and/or represent
cross-reactions with other pathogens, such as alphaviruses related to CHIKV (o’nyong-nyong
virus, Semliki Forest virus, and Sindbis virus), which are also known to be endemic in the
MENA region [16, 18, 65, 67–69]. CHIKV is known to circulate in Pakistan, Sudan, and
Yemen, and several anti-CHIKV serologic surveys and outbreaks have been published [7, 8,
50, 67, 70, 71]. Anti-CHIKV antibodies have also been reported from Egypt in the 1970s and
80s, and the country has experienced recent DENV outbreaks and is known to harbor Ae.
aegypti [2, 72]. However, to our knowledge, no CHIKV outbreaks have yet been reported in
Egypt.
Anti-DENV and anti-CHIKV IgG seroprevalence in Qatar
A seroprevalence of 3.5% for both anti-DENV and anti-CHIKV IgG was detected among
Qatar nationals in our study despite that neither Ae. aegypti, Ae. albopictus, nor autochthonous
transmission of either virus, have ever been reported in Qatar to our knowledge. This may rep-
resent travel-acquired infections and/or cross-reactions with related viruses. This low sero-
prevalence does not substantiate the need for routine DENV vaccination in Qatar, particularly
given the recommendation that DENV seroprevalence be� 70% in the age group targeted for
vaccination to maximize cost-effectiveness and public health impact [73]. Moreover, the risk
of transfusion-transmitted DENV or CHIKV through contaminated blood products is likely
low given that the presence of IgG likely represents past exposure after the viremic phase of
infection has resolved, and that our samples were not collected in a known outbreak setting
[74]. Nevertheless, ongoing surveillance for Ae. aegypti and Ae. albopictus is warranted in the
country, given that vector control remains the primary strategy for outbreak prevention and
control, and in light of the recent outbreaks that have occurred in neighboring Saudi Arabia
and Yemen [4, 8, 49, 75]. The low seropevalence among Qatari nationals indicates a lack of
herd immunity and susceptibility to DENV and CHIKV outbreaks.
Our study has several strengths but also important limitations. Strengths of our study
include its large sample size and diverse population. Not only were we able to estimate anti-
DENV and anti-CHIKV IgG seroprevalence among adults from MENA countries in which
major epidemiologic knowledge gaps exist, but we were also able to compare estimates against
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Asian nationals from hyper-endemic countries known to carry a considerable burden of
DENV and CHIKV disease. A major limitation of our study is our reliance on IgG ELISA and
lack of confirmatory viral neutralization testing, the gold standard for serodiagnosis of arbovi-
ruses, which was not performed due to resource limitations. Viral neutralization was per-
formed in only 5% of anti-DENV and 17% of anti-CHIKV serologic studies in the MENA
region in our systematic reviews, with cross reactions to antigenically similar viruses identified
in multiple studies resulting in lower attributable prevalence [1, 2]. Documented anti-DENV
antibody cross-reaction with West Nile virus, yellow fever virus (natural and vaccine), Zika
virus (e.g. in India and Philippines), or other flaviviruses may account for some of the observed
seropositivity in our study, while for anti-CHIKV antibodies, cross-reactions to o’nyong-
nyong virus, Semliki Forest virus, and Sindbis virus may have occurred. The lack of travel his-
tory limits conclusions that can be made regarding other countries, where DENV and CHIKV
exposure may have occurred. The lack of IgM or PCR testing limits inference concerning the
timing of infections or occurrences of co-infections. Finally, our limited sample of adult male
migrants residing in Qatar may not be representative of the general populations in their
respective countries (including females), nor adequately matched to one another for the
region-level analyses, although the vast majority of these migrants arrived in Qatar in recent
years [27, 28]. Given these limitations, caution must be maintained in extrapolating the sero-
logic results in our study to the broader country or region levels [15].
Conclusion
Exposure to DENV and CHIKV is low among Qatar and other MENA nationals compared to
Asian nationals, suggesting a lower burden of DENV and CHIKV disease in the MENA coun-
tries. Antibodies to both viruses were detected in nationals from all MENA countries except
Iran, supporting the need for further research to understand the epidemiology of DENV and
CHIKV, and the co-circulating viruses that cause serologic cross-reactions, in the MENA. The
findings in our study do not support the need for travellers to Qatar to take measures to pre-
vent DENV and CHIKV infections while in Qatar. Surveillance for Ae. aegypti and Ae. albopic-
tus should be implemented in countries in which autochthonous transmission of DENV or
CHIKV has not yet been reported.
Supporting information
S1 Table. Raw dataset containing anti-DENV and anti-CHIKV IgG results.
(XLSX)
Acknowledgments
The authors thank Ms. Adona Canlas for administrative support and Mrs. Nadima Haj Ali for
help with data entry and analysis. The authors are additionally grateful for the infrastructure
support provided by the Biostatistics, Epidemiology, and Biomathematics Research Core at
Weill Cornell Medicine-Qatar. The findings achieved herein are solely the responsibility of the
authors.
Author Contributions
Conceptualization: John M. Humphrey, John Schieffelin, Laith J. Abu-Raddad, Gheyath K.
Nasrallah.
Formal analysis: Soha R. Dargham.
Dengue and chikungunya among Qatari and immigrants in Qatar
PLOS ONE | https://doi.org/10.1371/journal.pone.0211574 January 31, 2019 9 / 13
Methodology: Enas S. Al-Absi, Munia M. Hamdan, Sara S. Okasha, Diyna M. Al-Trmanini,
Hend G. El-Dous, Gheyath K. Nasrallah.
Resources: Laith J. Abu-Raddad, Gheyath K. Nasrallah.
Writing – original draft: John M. Humphrey.
Writing – review & editing: Enas S. Al-Absi, Munia M. Hamdan, Sara S. Okasha, Diyna M.
Al-Trmanini, Hend G. El-Dous, John Schieffelin, Laith J. Abu-Raddad, Gheyath K.
Nasrallah.
References
1. Humphrey JM, Cleton NB, Reusken CB, Glesby MJ, Koopmans MP, Abu-Raddad LJ. Dengue in the
Middle East and North Africa: A Systematic Review. PLoS Negl Trop Dis. 2016; 10(12):e0005194.
https://doi.org/10.1371/journal.pntd.0005194 PMID: 27926925
2. Humphrey JM, Cleton NB, Reusken C, Glesby MJ, Koopmans MPG, Abu-Raddad LJ. Urban Chikungu-
nya in the Middle East and North Africa: A systematic review. PLoS Negl Trop Dis. 2017; 11(6):
e0005707. https://doi.org/10.1371/journal.pntd.0005707 PMID: 28651007
3. World Health Organization Regional Office for the Eastern Mediterranean. Dengue in Pakistan. Wkly
Epi Monitor. 2013; 6(52). Available from: www.emro.who.int/surveillance-forecasting-response/weekly-
epidemiological-monitor/. Accessed 7 May 2018.
4. World Health Organization Regional Office for the Eastern Mediterranean. Dengue fever in Yemen.
2010; 3(23). Available from: www.emro.who.int/surveillance-forecasting-response/weekly-
epidemiological-monitor/. Accessed 7 May 2018.
5. World Health Organization Regional Office for the Eastern Mediterranean. Dengue fever in Sudan:
cases continue to rise. 2010; 3(11). Available from: www.emro.who.int/surveillance-forecasting-
response/weeklyepidemiological-monitor/. Accessed 5 May 2018.
6. World Health Organization Regional Office for the Eastern Mediterranean. Chikungunya Outbreak in
Pakistan. Wkly Epi Monitor. 2017; 10(19). Available from: http://www.emro.who.int/surveillance-
forecasting-response/weekly-epidemiological-monitor/. Accessed 2 May 2018.
7. Gould LH, Osman MS, Farnon EC, Griffith KS, Godsey MS, Karch S, et al. An outbreak of yellow fever
with concurrent chikungunya virus transmission in South Kordofan, Sudan, 2005. Trans R Soc Trop
Med Hyg. 2008; 102(12):1247–54. https://doi.org/10.1016/j.trstmh.2008.04.014 PMID: 18502458
8. Malik MR, Mnzava A, Mohareb E, Zayed A, Al Kohlani A, Thabet AAK, et al. Chikungunya outbreak in
Al-Hudaydah, Yemen, 2011: Epidemiological characterization and key lessons learned for early detec-
tion and control. J Epidemiol Glob Health. 2014; 4(3):203–11. https://doi.org/10.1016/j.jegh.2014.01.
004 PMID: 25107656
9. The World Bank Group. Climate Change Knowledge Portal. Washington D.C., 2018. Available from:
http://sdwebx.worldbank.org/climateportal/. Accessed 15 October 2018.
10. Ducheyne E, Tran Minh NN, Haddad N, Bryssinckx W, Buliva E, Simard F, et al. Current and future dis-
tribution of Aedes aegypti and Aedes albopictus (Diptera: Culicidae) in WHO Eastern Mediterranean
Region. Int J Health Geogr. 2018; 17(1):4. https://doi.org/10.1186/s12942-018-0125-0 PMID:
29444675
11. Qatar Ministry of Development Planning and Statistics. Qatar’s Fourth National Human Development
Report: Realising Qatar National Vision 2030, The Right to Development. Doha, Qatar 2015. Available
from: http://hdr.undp.org/sites/default/files/qatar_nhdr4_english_15june2015.pdf. Accessed 7 May
2018.
12. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and
burden of dengue. Nature. 2013; 496(7446):504–7. https://doi.org/10.1038/nature12060 PMID:
23563266
13. Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J
Med. 2015; 372(13):1231–9. https://doi.org/10.1056/NEJMra1406035 PMID: 25806915
14. Bravo L, Roque VG, Brett J, Dizon R, L’Azou M. Epidemiology of dengue disease in the Philippines
(2000–2011): a systematic literature review. PLoS Negl Trop Dis. 2014; 8(11):e3027. https://doi.org/10.
1371/journal.pntd.0003027 PMID: 25375119
15. De Bel-Air F. Demography, Migration, and Labour Market in Qatar, Explanatory Note No. 8/2014. Euro-
pean University Institute and Gulf Research Center, Gulf Labour Market and Migration programme of
the Migration Policy Center (MPC) and the Gulf Research Center; 2014. Available at: http://gulfmigra-
tion.eu Available at. Accessed March 20, 2018.
Dengue and chikungunya among Qatari and immigrants in Qatar
PLOS ONE | https://doi.org/10.1371/journal.pone.0211574 January 31, 2019 10 / 13
16. Barakat AM, Smura T, Kuivanen S, Huhtamo E, Kurkela S, Putkuri N, et al. The Presence and Sero-
prevalence of Arthropod-Borne Viruses in Nasiriyah Governorate, Southern Iraq: A Cross-Sectional
Study. Am J Trop Med Hyg. 2016; 94(4):794–9. https://doi.org/10.4269/ajtmh.15-0622 Epub 2016 Feb
15. PMID: 26880770
17. Aghaie A, Aaskov J, Chinikar S, Niedrig M, Banazadeh S, Mohammadpour HK. Frequency of dengue
virus infection in blood donors in Sistan and Baluchestan province in Iran. Transfus Apher Sci. 2014; 50
(1):59–62. https://doi.org/10.1016/j.transci.2013.07.034 PMID: 24332363
18. Ibrahim SH, Darwish MA, Wahdan MH, el-Ghoroury AA. Serologic survey of Kuwait population for evi-
dence of group A arbovirus infection. J Egypt Public Health Assoc. 1973; 48(5):308–24. PMID:
4789151
19. Ibrahim SH, Darwish MA, Wahdan MH, El Ghoroury AAA. Survey for antibodies against group B arbovi-
ruses in man in Kuwait. J Egypt Public Health Assoc. 1974; 49(2):77–95. PMID: 4427084
20. Ergunay K, Saygan MB, Aydogan S, Litzba N, Niedrig M, Pinar A, et al. Investigation of dengue virus
and yellow fever virus seropositivities in blood donors from central/Northern Anatolia, Turkey. Mikro-
biyoloji Bulteni. 2010; 44(3):415–24. PMID: 21063991
21. Tezcan S, Kizildamar S, Ulger M, Aslan G, Tiftik N, Ozkul A, et al. Flavivirus seroepidemiology in blood
donors in Mersin province, Turkey. Mikrobiyoloji bulteni. 2014; 48(4):606–17. PMID: 25492656
22. Ashshi AM. Serodetection of Dengue virus and its antibodies among blood donors in the western region
of Saudi Arabia: a preliminary study. Blood Transfus. 2015; 13(1):135–8. https://doi.org/10.2450/2014.
0134-14 PMID: 25369603
23. AbuOdeh R, Al-Mawlawi N, Al-Qahtani AA, Bohol MF, Al-Ahdal MN, Hasan HA, et al. Detection and
genotyping of torque teno virus (TTV) in healthy blood donors and patients infected with HBV or HCV in
Qatar. J Med Virol. 2015; 87(7):1184–91. https://doi.org/10.1002/jmv.24146 PMID: 25676255
24. AbuOdeh RO, Al-Absi E, Ali NH, Khalili M, Al-Mawlawi N, Hadwan TA, et al. Detection and phylogenetic
analysis of human pegivirus (GBV-C) among blood donors and patients infected with hepatitis B virus
(HBV) in Qatar. J Med Virol. 2015; 87(12):2074–81. https://doi.org/10.1002/jmv.24289 PMID:
26058920
25. Al-Qahtani AA, Alabsi ES, AbuOdeh R, Thalib L, El Zowalaty ME, Nasrallah GK. Prevalence of anello-
viruses (TTV, TTMDV, and TTMV) in healthy blood donors and in patients infected with HBV or HCV in
Qatar. Virol J. 2016; 13(1):208. https://doi.org/10.1186/s12985-016-0664-6 PMID: 28031027
26. Nasrallah GK, Al Absi ES, Ghandour R, Ali NH, Taleb S, Hedaya L, et al. Seroprevalence of hepatitis E
virus among blood donors in Qatar (2013–2016). Transfusion. 2017; 57(7):1801–7. https://doi.org/10.
1111/trf.14116 PMID: 28453178
27. Dargham SR, Nasrallah GK, Al-Absi ES, Mohammed LI, Al-Disi RS, Nofal MY, et al. Herpes Simplex
Virus Type 2 Seroprevalence among Different National Populations of Middle East and North African
Men. Sex Transm Dis. 2018; 45(7):482–487. https://doi.org/10.1097/OLQ.0000000000000791 PMID:
29465656
28. Nasrallah GK, Dargham SR, Mohammed LI, Abu-Raddad LJ. Estimating seroprevalence of herpes sim-
plex virus type 1 among different Middle East and North African male populations residing in Qatar. J
Med Virol. 2018; 90(1):184–90. https://doi.org/10.1002/jmv.24916 PMID: 28817197
29. NovaTec Immunodiagnostica GmbH. Dengue Virus IgG. Dietzenbach, Germany; 2018. Available from:
https://www.novatec-id.com/products/product/dengue-virus-igg.html. Accessed October 22, 2018.
30. Euroimmun. ELISA. Lubeck, Germany; 2017. Available from: https://www.euroimmun.com/products/
indications/infektions-serologie/tropenkrankheiten/elisa/. Accessed March 20, 2018.
31. Euroimmun. Anti-Dengue Virus ELISA (IgG). Lubeck, Germany; 2016. Available from: https://www.
euroimmun.com/documents/Indications/Infections/Dengue/EI_266b_D_UK_A.pdf. Accessed March
20, 2018.
32. Prat CM, Flusin O, Panella A, Tenebray B, Lanciotti R, Leparc-Goffart I. Evaluation of commercially
available serologic diagnostic tests for chikungunya virus. Emerg Infect Dis. 2014; 20(12):2129–32.
https://doi.org/10.3201/eid2012.141269 PMID: 25418184
33. Mumtaz GR, Weiss HA, Thomas SL, Riome S, Setayesh H, Riedner G, et al. HIV among people who
inject drugs in the Middle East and North Africa: systematic review and data synthesis. PLoS medicine.
2014; 11(6):e1001663. https://doi.org/10.1371/journal.pmed.1001663 PMID: 24937136
34. Abu-Raddad LJ, Hilmi N, Mumtaz G, Benkirane M, Akala FA, Riedner G, et al. Epidemiology of HIV
infection in the Middle East and North Africa. AIDS. 2010; 24 Suppl 2:S5–23.
35. Harfouche M, Chemaitelly H, Kouyoumjian SP, Mahmud S, Chaabna K, Al-Kanaani Z, et al. Hepatitis C
virus viremic rate in the Middle East and North Africa: Systematic synthesis, meta-analyses, and meta-
regressions. PLoS One. 2017; 12(10):e0187177. https://doi.org/10.1371/journal.pone.0187177 PMID:
29088252
Dengue and chikungunya among Qatari and immigrants in Qatar
PLOS ONE | https://doi.org/10.1371/journal.pone.0211574 January 31, 2019 11 / 13
36. Mahmud S, Al-Kanaani Z, Chemaitelly H, Chaabna K, Kouyoumjian SP, Abu-Raddad LJ. Hepatitis C
virus genotypes in the Middle East and North Africa: Distribution, diversity, and patterns. J Med Virol.
2018; 90(1):131–41. https://doi.org/10.1002/jmv.24921 PMID: 28842995
37. Vongpunsawad S, Intharasongkroh D, Thongmee T, Poovorawan Y. Seroprevalence of antibodies to
dengue and chikungunya viruses in Thailand. PloS one. 2017; 12(6):e0180560. https://doi.org/10.1371/
journal.pone.0180560 PMID: 28662144
38. Low SL, Lam S, Wong WY, Teo D, Ng LC, Tan LK. Dengue seroprevalence of healthy adults in Singa-
pore: serosurvey among blood donors, 2009. Am J Trop Med Hyg. 2015; 93(1):40–5. https://doi.org/10.
4269/ajtmh.14-0671 PMID: 26013376
39. Ranjan P, Natarajan V, Bajpai M, Gupta E. High Seroprevalence of Dengue Virus Infection in Blood
Donors From Delhi: A Single Centre Study. J Clin Diagn Res. 2016; 10(10):DC08–DC10. https://doi.
org/10.7860/JCDR/2016/21262.8711 PMID: 27891337
40. Alera MT, Srikiatkhachorn A, Velasco JM, Tac-An IA, Lago CB, Clapham HE, et al. Incidence of Dengue
Virus Infection in Adults and Children in a Prospective Longitudinal Cohort in the Philippines. PLoS Negl
Trop Dis. 2016; 10(2):e0004337. https://doi.org/10.1371/journal.pntd.0004337 PMID: 26845762
41. Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev
Immunol. 2011; 29:587–619. https://doi.org/10.1146/annurev-immunol-031210-101315 PMID:
21219187
42. Forshey BM, Stoddard ST, Morrison AC. Dengue Viruses and Lifelong Immunity: Reevaluating the
Conventional Wisdom. J Infect Dis. 2016; 214(7):979–81. https://doi.org/10.1093/infdis/jiw102 PMID:
26984147
43. Ibrahim SA, Mustafa OM, Mukhtar MM, Saleh EA, El Mubarak HS, Abdallah A, et al. Measles in subur-
ban Khartoum: An epidemiological and clinical study. Trop Med Int Health. 2002; 7(5):442–9. PMID:
12000654
44. Malik A, Earhart K, Mohareb E, Saad M, Saeed M, Ageep A, et al. Dengue hemorrhagic fever outbreak
in children in Port Sudan. J Infect Public Health. 2011; 4(1):1–6. https://doi.org/10.1016/j.jiph.2010.08.
001 PMID: 21338953
45. Himatt S, Osman KE, Okoued SI, Seidahmed OE, Beatty ME, Soghaier MA, et al. Sero-prevalence of
dengue infections in the Kassala state in the eastern part of the Sudan in 2011. J Infect Public Health.
2015.
46. Soghaier MA, Mahmood SF, Pasha O, Azam SI, Karsani MM, Elmangory MM, et al. Factors associated
with dengue fever IgG sero-prevalence in South Kordofan State, Sudan, in 2012: Reporting prevalence
ratios. J Infect Public Health. 2014; 7(1):54–61. https://doi.org/10.1016/j.jiph.2013.07.008 PMID:
24210245
47. Adam I, Jumaa AM, Elbashir HM, Karsany MS. Maternal and perinatal outcomes of dengue in PortSu-
dan, Eastern Sudan. Virology J. 2010; 7(153).
48. Bin Ghouth AS, Amarasinghe A, Letson GW. Dengue outbreak in Hadramout, Yemen, 2010: an epide-
miological perspective. Am J Trop Med Hyg. 2012; 86(6):1072–6. https://doi.org/10.4269/ajtmh.2012.
11-0723 PMID: 22665621
49. Madani TA, Abuelzein ETME, Al-Bar HMS, Azhar EI, Kao M, Alshoeb HO, et al. Outbreak of viral hem-
orrhagic fever caused by dengue virus type 3 in Al-Mukalla, Yemen. BMC Infect Dis. 2013; 13(1).
50. Rezza G, El-Sawaf G, Faggioni G, Vescio F, Al Ameri R, De Santis R, et al. Co-circulation of Dengue
and Chikungunya Viruses, Al Hudaydah, Yemen, 2012. Emerg Infect Dis. 2014; 20(8):1351–4. https://
doi.org/10.3201/eid2008.131615 PMID: 25061762
51. Qassem MAM, Jaawal AAT. Dengue fever or West Nile virus outbreak? Yemen 2013. Int J Infect Dis.
2014; 21:457.
52. Hisam A, Mahmood ur R, Khan MB, Kadir E, Azam N. Frequency of co-existence of dengue and malaria
in patients presenting with acute febrile illness. JPMA J Pak Med Assoc. 2014; 64(3):247–51. PMID:
24864593
53. Assir MZK, Masood MA, Ahmad HI. Concurrent dengue and malaria infection in Lahore, Pakistan dur-
ing the 2012 dengue outbreak. Int J Infect Dis. 2014; 18(1):41–6.
54. Kidwai AA, Jamal Q, Saher, Mehrunnisa, Farooqi FU, Saleem U. Serodiagnosis of dengue infection
using rapid immunochromatography test in patients with probable dengue infection. J Pak Med Assoc.
2010; 60(11):936–9. PMID: 21375198
55. Ijaz T, Ijaz S, Aslam S, Ahmad BM, Raja SA. A laboratory based study of dengue epidemic in the city of
Lahore during year 2011. Int J Infect Dis 2014; 21:136.
56. Khan E, Kisat M, Khan N, Nasir A, Ayub S, Hasan R. Demographic and clinical features of dengue fever
in Pakistan from 2003–2007: A retrospective cross- sectional study. PLoS ONE. 2010; 5(9):1–7.
Dengue and chikungunya among Qatari and immigrants in Qatar
PLOS ONE | https://doi.org/10.1371/journal.pone.0211574 January 31, 2019 12 / 13
57. Garabedian GA, Matossian RM, Musalli MN. Serologic evidence of arbovirus infection in Lebanon. J
Med Liban. 1971; 24(4):339–50. PMID: 5149804
58. Hatem J. The role of the laboratory in the surveillance of viral diseases in Lebanon. J Med Liban. 1972;
25(3):151–65. PMID: 5086703
59. Haddad N, Harbach RE, Chamat S, Bouharoun-Tayoun H. Presence of Aedes albopictus in Lebanon
and Syria. J Am Mosq Control Assoc. 2007; 23(2):226–8. https://doi.org/10.2987/8756-971X(2007)23
[226:POAAIL]2.0.CO;2 PMID: 17847859
60. Adawi SHAA. Presence of Aedes albopictus in Palestine–West Bank. Int J Trop Dis Health. 2012; 2
(4):301–10.
61. Mohammed YS, Gresikova M, Adamyova K, Ragib AHe-DK. Studies on arboviruses in Egypt. II. Contri-
bution of arboviruses to the aetiology of undiagnosed fever among children. J Hyg. 1970; 68(3):491–5.
PMID: 5272347
62. Darwish MA, Ibrahim AH. Prevalence of antibodies to arboviruses in Egypt. Results of a serologic sur-
vey among 1,113 university students. Am J Trop Med Hyg. 1975; 24(6 I):981–5.
63. World Health Organization. Dengue Fever—Egypt 2015. Available from: http://www.who.int/csr/don/
12-november-2015-dengue/en/. Accessed 7 May 2018.
64. Obaidat MM RA. First report on seroprevalence and risk factors of dengue virus in Jordan. Trans R Soc
Trop Med Hyg. 2018; 112(6):279–84. https://doi.org/10.1093/trstmh/try055 PMID: 29992312
65. Saidi S. Survey of antibodies to arboviruses in human population of Iran. Pahlavi Med J. 1971; 2
(3):485–90.
66. Chinikar S, Ghiasi SM, Shah-Hosseini N, Mostafavi E, Moradi M, Khakifirouz S, et al. Preliminary study
of dengue virus infection in Iran. Travel Med Infect Dis. 2013; 11(3):166–9. https://doi.org/10.1016/j.
tmaid.2012.10.001 PMID: 23194952
67. Darwish MA, Hoogstraal H, Roberts TJ, Ahmed IP, Omar F. A sero-epidemiological survey for certain
arboviruses (Togaviridae) in Pakistan. Trans R Soc Trop Med Hyg. 1983; 77(4):442–5. PMID: 6314612
68. Woodruff PWR, Morrill JC, Burans JP, Hyams KC, Woody JN. A study of viral and rickettsial exposure
and causes of fever in Juba, southern Sudan. Trans R Soc Trop Med Hyg. 1988; 82(5):761–6. PMID:
2855284
69. Salim AR, Porterfield JS. A serological survey on arbovirus antibodies in the Sudan. Trans R Soc Trop
Med Hyg. 1973; 67(2):206–10. PMID: 4784057
70. World Health Organization Regional Office for the Eastern Mediterranean. Chikungunya in Somalia.
Wkly Epi Monitor. 2016; 9(24). Available from: www.emro.who.int/surveillance-forecasting-response/
weekly-epidemiological-monitor/. Accessed 7 May 2018.
71. ProMED-mail. Viral hemorrhagic fever: (Darfur) fatal, WHO, MOH. ProMED-mail. 2015. 25 Oct:
20151102.3760616.<http://www.promedmail.org>. Accessed 7 May 2018.
72. Abozeid S EA, Schaffner F, Samy AM. Re-emergence of Aedes aegypti in Egypt. Lancet Infect Dis.
2018; 18(2):142–3.
73. World Health Organization. Dengue vaccine: WHO position paper–July 2016. Wkly Epidemiol Rec.
2016; 91:349–64. PMID: 27476189
74. Busch MP, Sabino EC, Brambilla D, Lopes ME, Capuani L, Chowdhury D, et al. Duration of Dengue
Viremia in Blood Donors and Relationships Between Donor Viremia, Infection Incidence and Clinical
Case Reports During a Large Epidemic. J Infect Dis. 2016; 214(1):49–54. https://doi.org/10.1093/infdis/
jiw122 PMID: 27302934
75. Aziz AT, Al-Shami SA, Mahyoub JA, Hatabbi M, Ahmad AH, Rawi CSM. An update on the incidence of
dengue gaining strength in Saudi Arabia and current control approaches for its vector mosquito. Parasit
Vectors. 2014; 7(1). https://doi.org/10.1186/s13071-014-0467-9
Dengue and chikungunya among Qatari and immigrants in Qatar
PLOS ONE | https://doi.org/10.1371/journal.pone.0211574 January 31, 2019 13 / 13
